ArticlePlacenta2025
Monocyte chemoattractant Protein-1 (MCP-1) decreases mineralization of the villous stroma in the macaque placenta.
Article in Placenta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- BRIDGING COTYLEDON PATHOLOGY AND PERFUSION IN HEALTHY PRIMATE PREGNANCY.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionPlacental insufficiency occurs when a fetus does not receive adequate oxygen and/or nutrients, leading to adverse pregnancy outcomes (APOs). Increased leukocyte density has been observed in placental inflammatory lesions, resulting in placental insufficiency and APOs. MCP-1 is a chemokine associated with inflammatory disease, that actively attracts leukocyte populations. We investigated the effects of a supraphysiological MCP-1 injection into the maternal-fetal interface (MFI), using the macaque pregnancy model.
methodsA placental injection of MCP-1 or saline was administered to macaques between gestational day (GD) 100-105, along the MFI. Acute effects (n = 2) and full-term effects (n = 8) were studied. Full-term pregnancies had maternal placental blood perfusion measured via dynamic contrast enhanced MRI, before and after injection. Fetoplacental tissues were collected near term (GD 155). Placental histopathology was investigated, along with decidual immune populations, MRI-defined maternal blood metrics, and fetal biometrics.
resultsAcutely, increased leukocyte clustering and decreased mineralization were observed within the villous stroma of MCP-1-treated cotyledons. Decreased villous mineralization with MCP-1 injection was also noted in full-term pregnancies, along with a proportional increase in decidual dendritic cells. MRI placental analysis revealed a trend of increased maternal blood flow and reduced fill time after MCP-1 injection, alongside healthy fetal biometrics. DISCUSSION: Although MCP-1 is typically associated with inflammation and tissue pathology, our study demonstrates that supraphysiological MCP-1 levels led to increased leukocyte clustering and reduced mineralization in the villous stroma, without impairing maternal blood perfusion or fetal growth. These findings suggest a beneficial role for MCP-1 in the context of placental function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.